Advertisement

Journal of Assisted Reproduction and Genetics

, Volume 30, Issue 11, pp 1477–1485 | Cite as

Clomiphene Citrate co-treatment with low dose urinary FSH versus urinary FSH for clomiphene resistant PCOS: randomized controlled trial

  • Mohamad E. Ghanem
  • Laila A. Elboghdady
  • Mohamad Hassan
  • Adel S. Helal
  • Ahmed GibreelEmail author
  • Maha Houssen
  • Mohamed E. Shaker
  • Ibrahiem Bahlol
  • Yaser Mesbah
Assisted Reproduction Technologies

Abstract

Purpose

The aim of this study was to examine the effect of clomiphene citrate [CC] co-administration during the use of exogenous low-dose urinary FSH [uFSH] for induction of ovulation in CC-resistant infertile PCOS women.

Methods

In a randomised controlled setting, 174 CC-resistant infertile PCOS women were randomized into two parallel groups; Group I received CC 100 mg/day for 5 days plus uFSH 37.5 IU/day while group II received only uFSH 37.5 IU /day. Subsequent increments of uFSH by 37.5 IU/day were made according to response. Primary outcome was ovulation rate. Secondary outcomes were clinical pregnancy rates, number of follicles, endometrial thickness, and gonadotropins consumption.

Results

Our results have demonstrated that group I compared to group II had significantly higher ovulation rate per intention to treat [ITT] [72.4 % vs. 34.2 %, p < 0.001]. Clinical pregnancy and live birth rates were comparable between the two groups. Group I consumed significantly lower total FSH dose and needed significantly shorter stimulation duration compared to group II.

Conclusion

CC co-administered during low dose HP uFSH versus uFSH for CC-resistant PCOS yields significantly higher ovulation rate and less consumption of FSH.

Keywords

Clomiphene resistant PCOS Chronic low dose FSH Ovulation induction PCOS Randomized controlled trial 

Notes

Acknowledgments

The authors acknowledge the efforts of Ms Nessma, Mr Salah in endocrinology laboratory for their role in serum sample processing and storage. Also we thank the nursing staff and centre secretary for their efforts in patient cycle filing throughout the trial.

Declaration of interest

The authors report no declarations of interest.

References

  1. 1.
    The Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS). Hum Reprod. 2012;27:14–24.CrossRefGoogle Scholar
  2. 2.
    Gianaroli L, Racowsky C, Geraedts J, Cedars M, Makrigiannakis A, Roger L. Best practices of ASRM and ESHRE: a journey through reproductive medicine. Hum Reprod. 2012;27:3365–79.PubMedCrossRefGoogle Scholar
  3. 3.
    Balen A. Strategies for ovulation induction in the management of anovulatory polycystic ovary syndrome. In: Azziz R, editor. The polycystic ovary syndrome: Current concepts on pathogenesis and clinical care. Springer Science, Business Media, LLC; 2007. p. 99–112.Google Scholar
  4. 4.
    Eijkemans J, Habbema D, Fauser C. Characteristics of the best prognostic evidence: an example on prediction of outcome after clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. Semin Reprod Med. 2003;1:39–47.Google Scholar
  5. 5.
    Palomba S, Fallo A, Zullo F. Management strategies for ovulation induction in women with PCOS and known clomiphene citrate resistance. Curr Opin Obstet Gynecol. 2009;21:465–73.PubMedCrossRefGoogle Scholar
  6. 6.
    White M, Polson W, Kiddy D, Sagle P, Watson H, Gilling-Smith C, et al. Induction of ovulation with low-dose gonadotropins in polycystic ovary syndrome: an analysis of 109 pregnancies in 225 women. J Clin Endocrinol Metab. 1996;81:3821–4.PubMedGoogle Scholar
  7. 7.
    Balasch J, Fabregues F, Creus M, Casamitjana R, Puerto B, Vanrell A. Recombinant human follicle-stimulating hormone for ovulation induction in polycystic ovary syndrome: a prospective, randomized trial of two starting doses in a chronic low-dose step-up protocol. J Assist Reprod Genet. 2000;17:561–5.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Homburg R, Hendriks L, König E, Anderson A, Balen H, Brincat M, et al. Clomifene citrate or low-dose FSH for the first-line treatment of infertile women with anovulation associated with polycystic ovary syndrome: a prospective randomized multinational study. Hum Reprod. 2012;27:468–73.PubMedCrossRefGoogle Scholar
  9. 9.
    Dickey P, Olar T, Taylor N, Curole N, Rye H. Sequential clomiphene citrate and human menopausal gonadotrophin for ovulation induction: comparison to clomiphene citrate alone and human menopausal gonadotrophin alone. Hum Reprod. 1993;8:56–9.PubMedGoogle Scholar
  10. 10.
    Bedaiwy M, Forman R, Mousa A, Al Inany H, Casper F. Cost-effectiveness of aromatase inhibitor co-treatment for controlled ovarian stimulation. Hum Reprod. 2006;22:2838–44.CrossRefGoogle Scholar
  11. 11.
    The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41–7.CrossRefGoogle Scholar
  12. 12.
    Fritz A, Speroff L. In: Frtiz MA, Speroff L, editors. Induction of ovulation in clinical gynecologic endocrinology and infertility. 8th ed. Philadelphia USA: Lippicott Williams; 2011. p. 1293–300.Google Scholar
  13. 13.
    World Health Organization. WHO Laboratory Manual for the Examination of Human Semen and Sperm-Cervical Mucus Interaction. 4th ed. Cambridge, UK: Cambridge University Press; 1999.Google Scholar
  14. 14.
    Trinder P. Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromagen. J Clin Pathol. 1969;22:158–61.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Wahlefeld W. Triglyceride: determination after enzymatic hydrolysis. In: Bergmeyer HU, editor. Methods of Enzymatic Analysis. 2 Englishth ed. New York and London: Verlag Chemie Weinhiem and Academic press, Inc; 2000. p. 1831.Google Scholar
  16. 16.
    Assmann G, Schriewer H, Schmitz G, Hagele O. Quantification of high-density-lipoprotien cholesterol by precipitation with phosphotungestic acid/MgCl2. Clin Chem. 1983;29:2026–30.PubMedGoogle Scholar
  17. 17.
    Friedwald T, Levy I, Fredrickson S. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.Google Scholar
  18. 18.
    Matthews R, Hosker P, Turner C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Mc Cann D, Kirkish L. Immunoassay. 1985;8:234–6.Google Scholar
  20. 20.
    Liberopoulos N, Mikhailidis P, Elisaf S. Diagnosis and management of the metabolic syndrome in obesity. Obes Rev. 2005;6:283–96.Google Scholar
  21. 21.
    Moran L, Teede H. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Hum Reprod Update. 2009;15:477–88.PubMedCrossRefGoogle Scholar
  22. 22.
    Homburg R. Clomiphene citrate—end of an era? A mini-review. Hum Reprod. 2005;20:2043–51.PubMedCrossRefGoogle Scholar
  23. 23.
    Imani B, Eijkemans J, te Velde R, Habbema D, Fauser C. Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. J Clin Endocrinol Metab. 1998;83:2361–5.PubMedGoogle Scholar
  24. 24.
    Hamilton-Fairley D, Kiddy D, Watson H, Paterson C, Franks S. Association of moderate obesity with a poor pregnancy outcome in women with polycystic ovary syndrome treated with low dose gonadotrophin. Br J Obstet Gynaecol. 1992;99:128–31.PubMedCrossRefGoogle Scholar
  25. 25.
    Yarali H, Basaran M, Yigit N, Bukulmez O, Bildirici I. Gonadotropin treatment using the low-dose step-up protocol in patients with clomiphene citrate [CC] resistant polycystic ovary syndrome (PCOS): factors affecting outcome. Fertil Steril. 2001;76:S207–20.CrossRefGoogle Scholar
  26. 26.
    Orviet R, Homburg R. Chronic ultra-low dose follicle-stimulating hormone regimen for patients with polycystic ovary syndrome: one click, one follicle, one pregnancy. Fertil Steril. 2009;S1:1533–5.CrossRefGoogle Scholar
  27. 27.
    Dale O, Tanbo T, Haug E, Åbyholm T. The impact of insulin resistance on the outcome of ovulation induction with low-dose follicle stimulating hormone in women with polycystic ovary syndrome. Hum Reprod. 1998;13:567–70.PubMedCrossRefGoogle Scholar
  28. 28.
    Wely V, Bayram N, van der Veen F, Bossuyt M. Predicting ongoing pregnancy following ovulation induction with recombinant FSH in women with polycystic ovary syndrome. Hum Reprod. 2005;20:1827–32.PubMedCrossRefGoogle Scholar
  29. 29.
    Andersen N, Balen H, Platteau P, Pettersson G, Arce C. Prestimulation parameters predicting live birth in anovulatory WHO Group II patients undergoing ovulation induction with gonadotrophins. Hum Reprod. 2010;25:1988–95.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Mohamad E. Ghanem
    • 1
    • 2
  • Laila A. Elboghdady
    • 1
    • 2
  • Mohamad Hassan
    • 1
    • 2
  • Adel S. Helal
    • 1
    • 2
  • Ahmed Gibreel
    • 2
    Email author
  • Maha Houssen
    • 3
  • Mohamed E. Shaker
    • 4
  • Ibrahiem Bahlol
    • 1
    • 2
  • Yaser Mesbah
    • 2
  1. 1.Mansoura Integrated Fertility CenterMansouraEgypt
  2. 2.Department of Obestetrics & Gynecology, Mansoura Faculty of MedicineMansouraEgypt
  3. 3.Department of Biochemistry, Faculty of PharmacyDamanhur UniversityDamanhurEgypt
  4. 4.Department of Pharmacology & Toxicology, Faculty of PharmacyMansoura UniversityMansouraEgypt

Personalised recommendations